Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany
- PMID: 12410347
- DOI: 10.1007/s00430-002-0123-4
Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany
Abstract
Varicella is a potentially serious infection not only in immunocompromised individuals but also in otherwise healthy adults and children. Vaccination plays an important role in preventing the disease and its sequelae. A universal vaccination in childhood is expected to reduce substantially the number of uncomplicated cases of varicella and decrease the number of complicated cases requiring hospitalisation. To generate data as basis for decisions of the health authorities concerning prevention of varicella, epidemiological and health-economic data were collected in two studies. Using an age-structured decision analytic model the benefits, costs and cost effectiveness of a varicella immunisation program for a period of 30 years were assessed. It was shown that after the first year of life seroprevalence rates increased steadily and reached 62% among the 4- to 5-year olds and 94% among the 10- to 11-year olds, respectively; 90% of varicella patients were younger than 12 years. A severe course was assessed for 16.3% of the cases. Overall incidence of complications was estimated to be 5.7%. A routine varicella vaccination program targeting healthy children could prevent 82.7% of varicella cases and over 4,700 major complications per year provided the coverage level was 85%. Under these conditions the elimination of varicella is predicted to be achievable within 18 years. It is expected that a combined measles, mumps, rubella and varicella vaccine could provide the required coverage. Average yearly discounted net cost savings of universal childhood vaccination are 51 million Euro with a benefit-cost ratio of 4.12. Childhood vaccination with catch-up of adolescents provides additional clinical benefits. The break-even point indicating first net savings could be achieved already 3 years after the implementation of the vaccination program. In summary, routine childhood varicella vaccination appears to be a highly efficient strategy to significantly reduce the sizeable burden of varicella and would lead to net savings from both the societal but also the payer perspective.
Similar articles
-
[Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].Klin Padiatr. 2006 Jul-Aug;218(4):203-12. doi: 10.1055/s-2005-836610. Klin Padiatr. 2006. PMID: 16819701 German.
-
Economic evaluation of varicella vaccination in Spain: results from a dynamic model.Vaccine. 2006 Nov 17;24(47-48):6980-9. doi: 10.1016/j.vaccine.2006.04.051. Epub 2006 May 4. Vaccine. 2006. PMID: 16860909
-
Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.Vaccine. 2008 Oct 16;26(44):5619-26. doi: 10.1016/j.vaccine.2008.07.096. Epub 2008 Aug 22. Vaccine. 2008. PMID: 18723062
-
Clinical and economic considerations of vaccination against varicella.Pharmacotherapy. 1997 Jan-Feb;17(1):133-9. Pharmacotherapy. 1997. PMID: 9017774 Review.
-
A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.Int J Infect Dis. 2007 Nov;11 Suppl 2:S49-55. doi: 10.1016/S1201-9712(07)60022-8. Int J Infect Dis. 2007. PMID: 18162247 Review.
Cited by
-
Microbiology laboratory and the management of mother-child varicella-zoster virus infection.World J Virol. 2016 Aug 12;5(3):97-124. doi: 10.5501/wjv.v5.i3.97. World J Virol. 2016. PMID: 27563537 Free PMC article. Review.
-
Economic burden of varicella in children 1-12 Years of age in Hungary, 2011-2015.BMC Infect Dis. 2017 Jul 14;17(1):495. doi: 10.1186/s12879-017-2575-6. BMC Infect Dis. 2017. PMID: 28705150 Free PMC article.
-
How did the adoption of wP-pentavalent affect the global paediatric vaccine coverage rate? A multicountry panel data analysis.BMJ Open. 2022 Apr 4;12(4):e053236. doi: 10.1136/bmjopen-2021-053236. BMJ Open. 2022. PMID: 35379619 Free PMC article.
-
Varicella vaccination in Europe - taking the practical approach.BMC Med. 2009 May 28;7:26. doi: 10.1186/1741-7015-7-26. BMC Med. 2009. PMID: 19476611 Free PMC article. Review.
-
Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.BMC Infect Dis. 2017 May 18;17(1):353. doi: 10.1186/s12879-017-2445-2. BMC Infect Dis. 2017. PMID: 28521810 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical